21.77

0.59% -0.13

Bioage Labs Inc (BIOA)

Overview News Price History Discussions Forecast

Bioage Labs Inc stock is traded at $21.77, with a volume of 1.03M. It is down -0.59% in the last 24 hours and down -4.64% over the past month. Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

Previous Close:

$21.90

Open:

$21.9

24h Volume:

1.03M

Relative Volume:

1.96

Market Cap:

$967.74M

Revenue:

$10.32M

Net Income/Loss:

$-89.93M

P/E Ratio:

-9.0467

EPS:

-2.4064

Net Cash Flow:

$-88.63M

1W Performance:

-4.56%

1M Performance:

-4.64%

6M Performance:

+15.74%

1Y Performance:

+363.19%

1-Day Range:

$21.34

$22.32

1-Week Range:

$21.19

$23.75

52-Week Range:

$4.11

$25.95

Bioage Labs Inc Stock (BIOA) Company Profile

Name

Bioage Labs Inc

Sector

Healthcare (1071)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

510-806-1445

Address

5885 HOLLIS STREET, EMERYVILLE

Employee

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

BIOA's Discussions on Twitter

Compare BIOA vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BIOA Bioage Labs Inc	21.77	967.74M	10.32M	-89.93M	-88.63M	-2.4064
TAK Takeda Pharmaceutical Co Adr	17.24	55.06B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.78	43.07B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	30.81	35.88B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.35	31.59B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	528.47	26.32B	3.17B	1.29B	1.01B	27.09

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-26	Initiated	Needham	Buy
Feb-25-26	Initiated	Oppenheimer	Outperform
Feb-18-26	Upgrade	Jefferies	Hold → Buy
Jan-27-26	Initiated	Piper Sandler	Overweight
Dec-05-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Oct-22-25	Upgrade	Citigroup	Neutral → Buy
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-09-24	Downgrade	Citigroup	Buy → Neutral
Dec-09-24	Downgrade	Jefferies	Buy → Hold
Oct-21-24	Initiated	Citigroup	Buy
Oct-21-24	Initiated	Jefferies	Buy
Oct-21-24	Initiated	Morgan Stanley	Overweight

View All

Bioage Labs Inc Stock (BIOA) Latest News

Jul 19, 2026

BioAge Labs (BIOA) price target increased by 44.67% to 44.27 - MSN

Jul 19, 2026

Price to earnings forward of BioAge Labs, Inc. – FWB:Y7G - TradingView

Jul 19, 2026

Jul 14, 2026

HitGen partner BioAge begins phase 2 trial of BGE-102 By Investing.com - Investing.com Nigeria

Jul 14, 2026

HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102 - TradingView

Jul 14, 2026

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction - The Manila Times

Jul 14, 2026

HitGen partner BioAge begins phase 2 trial of BGE-102 - Investing.com

Jul 14, 2026

Jul 13, 2026

Price to book forward of BioAge Labs, Inc. – DUS:Y7G - TradingView

Jul 13, 2026

Jul 10, 2026

BioAge Labs, Inc. begins Phase 2 trial for obesity and cardiovascular risk treatment - Traders Union

Jul 10, 2026

How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure - simplywall.st

Jul 10, 2026

Jul 09, 2026

BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained - TipRanks

Jul 09, 2026

Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $50 - Moomoo

Jul 09, 2026

Jul 07, 2026

Bioage Labs stock hits 52-week high at 25.8 USD By Investing.com - Investing.com Nigeria

Jul 06, 2026

Jul 03, 2026

Why BioAge Labs (BIOA) Is Up 6.3% After Starting QUELL-CV Phase 2 Trial For BGE-102 - Sahm

Jul 03, 2026

Jul 01, 2026

BioAge Labs principal accounting officer sells $1.57m in stock By Investing.com - Investing.com India

Jul 01, 2026

Form 4 Bioage Labs Inc For: 1 July By Investing.com - Investing.com Nigeria

Jul 01, 2026

BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: - GuruFocus

Jul 01, 2026

Bioage Labs Insider Sold Shares Worth $1,576,752, According to a Recent SEC Filing - Moomoo

Jul 01, 2026

BioAge Labs principal accounting officer sells $1.57m in stock - Investing.com

Jul 01, 2026

[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan

Jul 01, 2026